Aryl ether-substituted heterocyclic compounds as GLP1R agonists
The present invention relates to a novel aryl ether substituted heterocyclic compound having GLP1R agonist activity. Specifically, disclosed are a compound as a GLP1R agonist represented by formula (1), or a pharmaceutically acceptable salt, solvate, hydrate, isotope substituent or isomer thereof.
1 . A compound, which is:
or a pharmaceutically acceptable salt, solvate, enantiomer, or isotopic variation thereof.
2 . The compound of claim 1 , which is:
3 . The compound of claim 1 , which is a pharmaceutical acceptable salt of:
4 . A compound, which is:
or a pharmaceutically acceptable salt, solvate, enantiomer, or isotopic variation thereof.
5 . The compound of claim 4 , which is:
6 . The compound of claim 4 , which is a pharmaceutical acceptable salt of:
7 . A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 .
8 . The pharmaceutical composition of claim 7 , further comprising one or more pharmaceutically acceptable excipients.
9 . The pharmaceutical composition of claim 7 , further comprising one or more additional therapeutic agents.
10 . A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 4 .
11 . The pharmaceutical composition of claim 10 , further comprising one or more pharmaceutically acceptable excipients.
12 . The pharmaceutical composition of claim 10 , further comprising one or more additional therapeutic agents.